GPR65 as a potential immune checkpoint regulates the immune microenvironment according to pan-cancer analysis
Liangliang Wang,
Lele Sun,
Hao Sun,
Yunhong Xing,
Shidong Zhou,
Guoshuai An,
Jian Li,
Kang Ren,
Junhong Sun
Affiliations
Liangliang Wang
Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China
Lele Sun
Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China
Hao Sun
Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China
Yunhong Xing
Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China
Shidong Zhou
Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China
Guoshuai An
Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China
Jian Li
Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China
Kang Ren
Corresponding author.; Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China
Junhong Sun
Corresponding author. Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China.; Department of Forensic Medicine, Shanxi Medical University, Jinzhong, China
It has been reported that inhibition of GPR65 may be effective for the treatment of certain cancers. Nevertheless, the role of GPR65 in various cancers remains unknown. We conducted an exhaustive pan-cancer analysis of GPR65 using multiple databases, including TCGA, GTEx, BioGPS, HPA, cBioPortal, and GeneCards. GPR65 was found to be differentially expressed in various cancers and linked to tumor mutational burden (TMB), microsatellite instability (MSI), and Ploidy, playing a key function in the tumor microenvironment (TME). It is closely linked to the development of Th17 cells as well as Th1 and Th2 cells in certain cancers. Our findings indicate that the expression of GPR65 is highly linked with clinical prognosis, mutations, and immune cell infiltration. It was revealed as an indicator of patient prognosis as well as a possible immunomodulatory role. As a possible new immunological checkpoint, GPR65 could be a target for tumor immunotherapy.
